Browsing Tag

Partnering

580 posts

BI, MD Anderson Cancer Center Partner for Cancer Research and Virtual R&D Center
By

By
Boehringer Ingelheim (BI) and the University of Texas MD Anderson Cancer Center have formed a multi-year partnership to conduct collaborative research on therapies for various types of cancers, including the…

Takeda, Sosei Heptares Form $1.2-Billion R&D Partnership
By

By
Sosei Heptares, a Tokyo-headquartered pharmaceutical company, has entered into a strategic multi-target partnership with Takeda Pharmaceutical to discover, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor…

Celltrion Partners To Form New Biosimilars JV in China
By

By
Celltrion, an Incheon, Korea-based biopharmaceutical company developing innovator drugs and biosimilars, and Nan Fung Group, a Hong Kong-based conglomerate, have formed a joint-venture company, Vcell Healthcare, to develop biosimilars in…

Astellas, Frequency Therapeutics in $625-Million Deal for Hearing-Loss Drug
By

By
Astellas Pharma has entered into an exclusive license agreement, worth up to $625 million, with Frequency Therapeutics, a biopharmaceutical company focused on small-molecule drugs, to develop and commercialize Frequency Therapeutics’…

Sanofi Gains OTC Rights in US to Roche’s Flu Drug Tamiflu
By

By
Sanofi has signed an agreement with Roche for the exclusive over-the-counter (OTC) rights in the US to Roche’s Tamiflu (oseltamivir phosphate) for the prevention and treatment of influenza. Tamiflu is…

Gilead, Novartis Form Antiviral Drug Pact
By

By
Gilead Sciences has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Novartis will receive an upfront payment and…

BI Forms $1.2-Billion Deal with Bridge Therapeutics for Lung-Disease Drug
By

By
Boehringer Ingelheim (BI) has entered into a collaboration and license agreement, in a deal worth up to in up EUR 1.1 billion ($1.2 billion), with Bridge Biotherapeutics, a clinical-stage biopharmaceutical…

Gilead and Galapagos Enter $5-Billion Research and Development Deal
By

By
Gilead Sciences and Galapagos, a Mechelen, Belgium-based pharmaceutical company focused on small-molecules drugs in inflammation, fibrosis, and osteoarthritis, have entered into a 10-year global research and development collaboration in a…

Gilead, Carna BioSciences Form $470-Million Immuno-Oncology Pact
By

By
Gilead Sciences and Carna BioSciences, a biopharmaceutical company developing kinase inhibitor drugs for oncology, autoimmune, and neurological diseases, have entered into a research and development collaboration to develop and commercialize…

Vertex Makes Two Gene-Editing Deals, Worth Up to $1 Billion Each
By

By
Vertex Pharmaceuticals has made two deals, worth up to $1 billion each, to enhance its gene-editing capabilities in drug development. The company is expanding its collaboration with CRISPR Therapeutics, a…